Ravelcare Ltd (544629)
Latest quarterly results (Q4 FY26)
In its latest reported quarter, Q4 FY26, Ravelcare's revenue was ₹12.6 Cr (-13.9% year on year), and net profit ₹1.9 Cr (+30.0% year on year); the operating margin was 21.7%.
| Q4 FY26 (₹ Cr) | Value | YoY vs Q4 FY25 | QoQ |
|---|---|---|---|
| Revenue | ₹12.6 | -13.9% | — |
| Operating profit | ₹2.7 | +112.5% | — |
| Net profit | ₹1.9 | +30.0% | — |
| EPS (₹) | 2.84 | -5.3% | — |
| Operating margin | 21.7% | — | — |
📢 Recent Corporate Announcements
Ravelcare Limited has published its Annual Report for FY 2025-26 and scheduled its 8th Annual General Meeting (AGM) for September 23, 2026. For FY26, the company reported revenue from operations of ₹2,695.43 Lakhs (up 7.9% YoY) and a Profit After Tax of ₹515.40 Lakhs, representing a 19.1% net profit margin. The company maintains a debt-free balance sheet with net worth increasing to ₹3,740.84 Lakhs. In management commentary, the company highlighted the launch of its clinical haircare range 'Ravel PRO' to expand into quick commerce and marketplaces, alongside planned skincare launches in Q3.
- FY26 Revenue from operations grew 7.9% YoY to ₹2,695.43 Lakhs
- Profit after tax stood at ₹515.40 Lakhs, delivering a 19.1% net profit margin
- Company remains completely debt-free with net worth expanding to ₹3,740.84 Lakhs
- 8th AGM to be held virtually on September 23, 2026; e-voting cut-off date is September 16, 2026
Ravelcare Limited announced the commercial expansion of its 12-product 'Ravel PRO' haircare range and plans to launch an AI-diagnostic skincare line in H2 FY27. In July 2026, its first full month, Ravel PRO contributed approximately 20% incremental revenue to the company. The company also clarified that its planned backward integration manufacturing capex (funded via Rs 24.10 cr IPO proceeds) has been phased behind product launches, with funds currently held in fixed deposits. For FY26, Ravelcare reported Rs 26.95 cr in revenue (+7.9% YoY) and Rs 5.15 cr in PAT with zero debt.
- Ravel PRO delivered ~20% incremental revenue in its first full month (July 2026)
- Anti-Grey Serum alone sold about 3,500 units within its first 30 days
- AI-diagnostic derma-grade skincare range slated for launch in H2 FY27
- IPO proceeds of Rs 2,410.20 lakhs (Rs 2,191.10 lakhs net) for manufacturing capex remain unutilised in bank FDs pending plant scale finalisation
- Reported FY26 revenue of Rs 2,695.43 lakhs and PAT of Rs 515.40 lakhs with zero debt
Ravelcare Ltd's Board approved the re-appointment of Mr. Ayush Varma as Managing Director and Mr. Maheshkumar Varma as Whole-time Director for a 3-year term from June 20, 2027 to June 19, 2030, subject to shareholder approval at the ensuing 8th AGM. The Board also approved the re-appointment of M/s. VTSN & Associates LLP as Secretarial Auditors for FY2026-27. Additionally, the company is shifting its registered office within Malad West, Mumbai, effective August 26, 2026.
- Re-appointed MD Ayush Varma for a 3-year term from June 20, 2027 to June 19, 2030
- Re-appointed Whole-time Director Maheshkumar Varma for 3 years starting June 20, 2027
- M/s. VTSN & Associates LLP re-appointed as Secretarial Auditors for FY 2026-27
- Registered office shifted within Malad West, Mumbai, effective August 26, 2026
Ravelcare Limited announced board approval for key corporate and administrative decisions during its August 25, 2026 meeting. Managing Director Ayush Varma and Whole-time Director Maheshkumar Varma were re-appointed for 3-year terms effective June 20, 2027 to June 19, 2030, subject to shareholder approval at the 8th AGM. The board also approved shifting the registered office within Malad West, Mumbai, effective August 26, 2026. Additionally, M/s. VTSN & Associates LLP was re-appointed as secretarial auditor for FY 2026-27.
- Re-appointment of Managing Director Ayush Varma for a 3-year term from June 20, 2027 to June 19, 2030
- Re-appointment of Whole-time Director Maheshkumar Varma for a 3-year term from June 20, 2027 to June 19, 2030
- Registered office shifted locally within Malad (West), Mumbai effective August 26, 2026
- Re-appointment of M/s. VTSN & Associates LLP as Secretarial Auditor for FY 2026-27
Ravelcare Limited announced outcomes of its Board meeting held on August 25, 2026. The Board approved the re-appointment of Managing Director Mr. Ayush Varma and Whole-time Director Mr. Maheshkumar Varma for 3-year terms spanning June 20, 2027, to June 19, 2030, subject to shareholder approval. Additionally, the Board re-appointed M/s. VTSN & Associates LLP as Secretarial Auditors for FY 2026-27 and approved shifting its registered office within Malad (West), Mumbai, effective August 26, 2026.
- Re-appointed MD Ayush Varma for a 3-year tenure from June 20, 2027, to June 19, 2030
- Re-appointed Whole-time Director Maheshkumar Varma for 3 years from June 20, 2027, to June 19, 2030
- Secretarial Auditor M/s. VTSN & Associates LLP re-appointed for FY 2026-27
- Registered office shifted within Malad West, Mumbai, effective August 26, 2026
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
